Episode 223: ASCO GU 2023: Discussing KEYNOTE...

Shilpa Gupta joins us to discuss an X poll revealing equipoise about treatment approaches to resected high-risk upper tract urothelial cancer (UTUC). 

Rob Dreicer joins the show to discuss the FDA approval of Lutetium Lu 177 in the mHSPC space and how to contextualize the benefit/risk 

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting.

<span style= "text-decoration: underline;">TRANSCRIPT</span>

UROONCO BCa chief editor Dr. Benjamin Pradere talks to Assoc. Prof. Andrea Necchi (IT) at EMSO 2024 on the results of the interim analysis of SunRISe-4 study: TAR-200 plus cetrelimab or CET alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are in ...

<span class= "normaltextrun"><span style= "font-size: 11.0pt; line-height: 107%; font-family: 'Calibri',sans-serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: major-fareast; mso-ansi-language: EN-US; mso-f ...

Drs. Neeraj Agarwal and Todd Morgan discuss CONTACT-02, KEYNOTE-564, CheckMate-67T, and other notable studies featured at the 2024 ASCO Genitourinary Cancers Symposium, as well as additional key abstracts in prostate, kidney, and bladder cancers that will significantly influen ...